The role of 177LuDotatate peptide receptor radionuclide treatment in patients with metastatic well differentiated gastroenteropancreatic neuroendocrine neoplasms (GEP-NETs)

被引：0
|
作者：
Severi, S. [1 ]
Sansovini, M. [1 ]
Ianniello, A. [1 ]
Ambrosetti, A. [1 ]
Monti, M. [1 ]
Scarpi, E. [1 ]
Di Iorio, V. [1 ]
D'Errico, V. [1 ]
Ibrahim, T. [1 ]
Paganelli, G. [2 ]
机构：
[1] IRCCS IRST, Meldola, Italy
[2] IEO, Milan, Italy
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2013年 / 40卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
引用
收藏
页码：S140 / S140
页数：1
相关论文
共 50 条
  • [1] Efficacy of Peptide Receptor Radionuclide Therapy Treatment with 177Ludotatate in Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors
    Sansovini, M.
    Severi, S.
    Ambrosetti, A.
    Monti, M.
    Nanni, O.
    Bodei, L.
    Garaboldi, L.
    Bartolomei, M.
    Sarnelli, A.
    Paganelli, G.
    NEUROENDOCRINOLOGY, 2012, 96 : 57 - 58
  • [2] Surgery after Peptide Receptor Radionuclide Therapy (PRRT) in Patients with Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
    Bertani, E.
    Chiappa, A.
    Fazio, N.
    Grana, C.
    Bodei, L.
    Falconi, M.
    Ravizza, D.
    Spada, F.
    Andreoni, B.
    NEUROENDOCRINOLOGY, 2014, 99 (3-4) : 285 - 285
  • [3] Peptide receptor radionuclide therapy of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): From literature to practice
    Bournaud, C.
    Kelly, A.
    Hindie, E.
    Tenenbaum, F.
    Faivre-Chauvet, A.
    Courbon, F.
    Taieb, D.
    Dierickx, L. O.
    Coriat, R.
    Ansquer, C.
    MEDECINE NUCLEAIRE-IMAGERIE FONCTIONNELLE ET METABOLIQUE, 2017, 41 (01): : 42 - 54
  • [4] 177LuDotatate peptide receptor radionuclide treatment in patients with advanced well differentiated pancreatic neuroendocrine tumors (P-NET): results of a phase II prospective study
    Sansovini, M.
    Severi, S.
    Ambrosetti, A.
    Samelli, A.
    Nanni, O.
    Donati, C.
    Monti, M.
    Bodei, L.
    Bartolomei, M.
    Paganelli, G.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2012, 39 : S232 - S232
  • [5] The role of systemic inflammatory factors in gastroenteropancreatic neuroendocrine tumors (GEP-NETs) treated with peptide receptor radionuclide therapy (PRRT).
    Abou Jokh Casas, Estephany
    Lago, Nieves Martinez
    Cabezas Agricola, Jose Manuel
    Herranz, Urbano Anido
    Baron, Francisco
    Calvo, Ovidio Fernandez
    Varela, Maria Quindos
    Ferreiro, Silvia Varela
    Maseda, Alberto Carral
    De Matias Leralta, Jose Maria
    Seoane, Zulema Nogareda
    Castineira, Antia Cousillas
    Martinez de LLano, Sofia Rodriguez
    Mato Mato, Jose Antonio
    Catalina, Pablo Fernandez
    Fonseca, Omar Rodriguez
    Garcia, Gloria Muniz
    Bernardez, Beatriz
    Cameselle Teijeiro, Jose Manuel
    Nunez, Virginia Pubul
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [6] The role of 177Lu-Dotatate peptide receptor radionuclide treatment in patients with metastatic well differentiated gastrointestinal neuroendocrine tumors (GI-NETs)
    Severi, S.
    Sansovini, M.
    Ambrosetti, A.
    Ianniello, A.
    Scarpi, E.
    Nanni, O.
    Sarnelli, A.
    Di Iorio, V.
    Garaboldi, L.
    Matteucci, F.
    Bartolomei, M.
    Paganelli, G.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2012, 39 : S233 - S233
  • [7] Real-world efficacy and safety of peptide receptor radionuclide therapy (PRRT) in gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
    Abou Jokh Casas, Estephany
    Martinez, Nieves Purificacion
    Herranz, Urbano Anido
    Cabezas Agricola, Jose Manuel
    Ferreiro, Silvia Varela
    Maseda, Alberto Carral
    Calvo, Ovidio Fernandez
    Mato Mato, Jose Antonio
    Seoane, Zulema Nogareda
    Martinez de LLano, Sofia Rodriguez
    Varela, Maria Quindos
    Baron, Francisco
    Fonseca, Omar Rodriguez
    Castineira, Antia Cousillas
    Garcia, Gloria Muniz
    De Matias Leralta, Jose Maria
    Catalina, Pablo Fernandez
    Cameselle Teijeiro, Jose Manuel
    Bernardez, Beatriz
    Nunez, Virginia Pubul
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [8] Can tumor absorbed dose predict response to Peptide Receptor Radionuclide Therapy (PRRT) in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs)?
    Mileva, M.
    Marin, G.
    Levillain, H.
    van Bogaert, C.
    Critchi, G.
    Marin, C.
    Flamen, P.
    Karfis, I
    JOURNAL OF NEUROENDOCRINOLOGY, 2022, 34 : 153 - 153
  • [9] Current treatment strategies for patients with advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs)
    Inbal Uri
    Simona Grozinsky-Glasberg
    Clinical Diabetes and Endocrinology, 4 (1):
  • [10] Role of systemic inflammatory factors in gastroenteropancreatic neuroendocrine tumors (GEP-NETs) treated with peptide receptor radionuclide therapy (PRRT): From biology to theragnosis
    Casas, E. Abou-Jokh
    Martinez-Lagob, N.
    Araujo, M. C. Mallon
    Agricolac, J. M. Cabezas
    Seoaned, Z. Nogareda
    Castineirae, A. Cousillas
    Morellf, A. Ruibal
    Nuneza, V. Pubul
    REVISTA ESPANOLA DE MEDICINA NUCLEAR E IMAGEN MOLECULAR, 2023, 42 (03): : 156 - 162
12345